Cargando…

Type 1 Diabetes: Disease Stratification

Type 1 diabetes, a disorder characterized by immune-mediated loss of functional pancreatic beta cells, is a disease continuum with specific presymptomatic stages with defined risk of progression to symptomatic disease. Prognostic biomarkers have been developed for disease staging and for stratificat...

Descripción completa

Detalles Bibliográficos
Autores principales: Insel, Richard, Dutta, Sanjoy, Hedrick, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945911/
https://www.ncbi.nlm.nih.gov/pubmed/31988942
http://dx.doi.org/10.1159/000481131
_version_ 1783485258489921536
author Insel, Richard
Dutta, Sanjoy
Hedrick, Joseph
author_facet Insel, Richard
Dutta, Sanjoy
Hedrick, Joseph
author_sort Insel, Richard
collection PubMed
description Type 1 diabetes, a disorder characterized by immune-mediated loss of functional pancreatic beta cells, is a disease continuum with specific presymptomatic stages with defined risk of progression to symptomatic disease. Prognostic biomarkers have been developed for disease staging and for stratification of subjects that address the heterogeneity in rate of disease progression. Using biomarkers for stratification of subjects at different stages of type 1 diabetes will enable smaller and shorter intervention clinical trials with greater effect size. Addressing the heterogeneity of the disease will allow precision medicine-based approaches to prevention and interception of presymptomatic stages of disease and treatment and cure of symptomatic disease.
format Online
Article
Text
id pubmed-6945911
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-69459112020-01-27 Type 1 Diabetes: Disease Stratification Insel, Richard Dutta, Sanjoy Hedrick, Joseph Biomed Hub Article Type 1 diabetes, a disorder characterized by immune-mediated loss of functional pancreatic beta cells, is a disease continuum with specific presymptomatic stages with defined risk of progression to symptomatic disease. Prognostic biomarkers have been developed for disease staging and for stratification of subjects that address the heterogeneity in rate of disease progression. Using biomarkers for stratification of subjects at different stages of type 1 diabetes will enable smaller and shorter intervention clinical trials with greater effect size. Addressing the heterogeneity of the disease will allow precision medicine-based approaches to prevention and interception of presymptomatic stages of disease and treatment and cure of symptomatic disease. S. Karger AG 2017-11-21 /pmc/articles/PMC6945911/ /pubmed/31988942 http://dx.doi.org/10.1159/000481131 Text en Copyright © 2017 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Article
Insel, Richard
Dutta, Sanjoy
Hedrick, Joseph
Type 1 Diabetes: Disease Stratification
title Type 1 Diabetes: Disease Stratification
title_full Type 1 Diabetes: Disease Stratification
title_fullStr Type 1 Diabetes: Disease Stratification
title_full_unstemmed Type 1 Diabetes: Disease Stratification
title_short Type 1 Diabetes: Disease Stratification
title_sort type 1 diabetes: disease stratification
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945911/
https://www.ncbi.nlm.nih.gov/pubmed/31988942
http://dx.doi.org/10.1159/000481131
work_keys_str_mv AT inselrichard type1diabetesdiseasestratification
AT duttasanjoy type1diabetesdiseasestratification
AT hedrickjoseph type1diabetesdiseasestratification